[PDF][PDF] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): results of a …
D Cunningham, I Lang, V Lorusso… - J. Clin …, 2013 - hematologyandoncology.net
The safety profile for patients treated with bevacizumab was generally consistent with
previously reported data. Patients in the combination arm were more likely to experience an …
previously reported data. Patients in the combination arm were more likely to experience an …
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
E Vrdoljak, T Omrcen, M Boban, A Hrabar - Anti-cancer drugs, 2011 - journals.lww.com
The relative survival of elderly patients with metastatic colorectal cancer (mCRC) is
generally worse than that of younger patients because of more advanced stage at …
generally worse than that of younger patients because of more advanced stage at …
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label …
D Cunningham, I Lang, E Marcuello, V Lorusso… - The lancet …, 2013 - thelancet.com
Background Elderly patients are often under-represented in clinical trials of metastatic
colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus …
colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus …
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of …
MP Saunders, I Lang, E Marcuello, V Lorusso, J Ocvirk… - 2013 - ascopubs.org
3521 Background: Elderly patients (pts) are underrepresented in clinical trials. The open-
label phase III trial AVEX evaluated the benefit of adding bevacizumab (BEV) to …
label phase III trial AVEX evaluated the benefit of adding bevacizumab (BEV) to …
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer
A Naeim, PR Ward, HJ Wang, R Dichmann… - Journal of Geriatric …, 2013 - Elsevier
Objectives This study aims to determine the efficacy and tolerability of capecitabine (CAP)
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …
First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
J Feliu, A Salud, MJ Safont, C García-Girón… - British journal of …, 2014 - nature.com
Background: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is
effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The …
effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The …
[HTML][HTML] Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an …
Background In an ageing population, a greater proportion of geriatric patients will be
considered for systemic chemotherapy. Colorectal cancer (CRC) is a common malignancy …
considered for systemic chemotherapy. Colorectal cancer (CRC) is a common malignancy …
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
JA Rocha - Anti-Cancer Drugs, 2011 - journals.lww.com
Colorectal cancer (CRC) occurs predominantly in older people. It is the second leading
cause of death from cancer among adults. Statistical power to assess risk/benefit from …
cause of death from cancer among adults. Statistical power to assess risk/benefit from …
PRODIGE 20: Bevacizumab+ chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC) …
T Aparicio, O Bouche, E Francois, E Maillard… - 2015 - ascopubs.org
3541 Background: AVEX study has demonstrated increased progression-free survival (PFS)
with capecitabine+ bevacizumab compared to capecitabine alone in pts aged over 70 with …
with capecitabine+ bevacizumab compared to capecitabine alone in pts aged over 70 with …
Efficacy and safety of bevacizumab combined with first-line chemotherapy in elderly (≥ 75 Years) patients with metastatic colorectal cancer: A real-world study
E François, L Mineur, G Deplanque, P Laplaige… - Clinical Colorectal …, 2020 - Elsevier
Background Although elderly patients are the first concerned by colorectal cancer (CRC),
they are underrepresented in clinical trials. The real-world CASSIOPEE study was thus …
they are underrepresented in clinical trials. The real-world CASSIOPEE study was thus …